Hybrigenics Acquires Imaxio's Genomics Business | GenomeWeb

NEW YORK (GenomeWeb News) – French biopharmaceutical firm Hybrigenics said recently that it has acquired the genomics business of biotech company Imaxio for an undisclosed amount.

Hybrigenics said that it received €1.3 million ($1.8 million) through a private placement from Pradeyrol Development to help finance the deal. Pradeyrol is a majority stakeholder in Imaxio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.